Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06087289 | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(KANDOVA) | completed | Phase 1 / Phase 2 | 18 | Novakand Pharma ABINDUSTRY | 3 | Jun 8, 2025 | clinicaltrials |
| NCT05440942 | Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | completed | Phase 1 | 28 | Peter Hosein, MDOTHER | 1 | Jun 5, 2025 |
| clinicaltrials |
| NCT04358237 | Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.(LUPER) | completed | Phase 1 / Phase 2 | 28 | Antonio Calles BlancoOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03317327 | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors(REPORT) | completed | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT03914443 | A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma | completed | Phase 1 | 37 | National Cancer Center, JapanOTHER_GOV | 1 | May 31, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT04337970 | Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT02713386 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 147 | NRG OncologyOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT05054374 | A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03508570 | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT03299088 | Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations | completed | Phase 1 | 15 | Jonathan RiessOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT03554044 | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | completed | Phase 1 | 20 | University of California, San FranciscoOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT03897036 | Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) | completed | Phase 1 | 25 | Senhwa Biosciences, Inc.INDUSTRY | 1 | May 20, 2025 | clinicaltrials |
| NCT04121286 | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China | completed | Phase 1 | 17 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2025 | clinicaltrials |
| NCT04555837 | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | completed | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT02899078 | Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 31 | University of California, DavisOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06304805 | TGRX-326 Pharmacokinetic Food Effect Bioavailability Study | completed | Phase 1 | 24 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT03704688 | Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT02318771 | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | completed | Phase 1 | 41 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03784378 | Continued Access to RXDX-105 | completed | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03524326 | Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 40 | Aprea TherapeuticsINDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT03554473 | M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | May 9, 2025 | clinicaltrials |
| NCT03212469 | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer(ABIMMUNE) | completed | Phase 1 / Phase 2 | 54 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT00328562 | ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 | 13 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT01754987 | A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective | completed | Phase 1 / Phase 2 | 5 | Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT01848067 | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04581343 | A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients(PanCAN-SR1) | completed | Phase 1 | 10 | Pancreatic Cancer Action NetworkOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT05289908 | Intrathecal Pemetrexed for Leptomeningeal Metastasis | completed | Phase 1 / Phase 2 | 34 | The First Hospital of Jilin UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT02603965 | Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery | completed | Phase 1 | 25 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT03045497 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads | completed | Phase 1 | 15 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT01443260 | A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis | completed | Phase 1 / Phase 2 | 9 | Genelux GmbHINDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05383352 | A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas(SIRACUSA) | completed | Phase 1 | 177 | IpsenINDUSTRY | 7 | Apr 30, 2025 | clinicaltrials |
| NCT03054298 | CAR T Cells in Mesothelin Expressing Cancers | completed | Phase 1 | 65 | University of PennsylvaniaOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03076203 | Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) | completed | Phase 1 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04075396 | A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 29 | Janssen Research & Development, LLCINDUSTRY | 3 | Apr 29, 2025 | clinicaltrials |
| NCT04078269 | MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer(MIDRIXNEO) | completed | Phase 1 | 6 | University Hospital, GhentOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03324373 | Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) | completed | Phase 1 | 11 | Yousef ZakhariaOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | completed | Phase 1 / Phase 2 | 111 | NuCana plcOTHER | 3 | Apr 23, 2025 | clinicaltrials |
| NCT04339062 | Cemiplimab in AlloSCT/SOT Recipients With CSCC(CONTRAC) | completed | Phase 1 / Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | completed | Phase 1 / Phase 2 | 64 | Imugene LimitedINDUSTRY | 7 | Apr 16, 2025 | clinicaltrials |
| NCT02990481 | A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | Toray Industries, IncINDUSTRY | 2 | Apr 16, 2025 | clinicaltrials |
| NCT00576654 | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 73 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2025 | clinicaltrials |
| NCT02487095 | Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | completed | Phase 1 / Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04720976 | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 58 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03473756 | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma(FORT-2) | completed | Phase 1 | 37 | BayerINDUSTRY | 8 | Apr 9, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2025source: clinicaltrials